Despite many people believing the HIV crisis is “solved,” HIV remains a critical public health issue with more than 31,000[1] new diagnoses in the US each year.
Thankfully, as science and research have advanced, there are many tools available to help prevent HIV, including PrEP (pre-exposure prophylaxis) which is medicine that prevents people from getting HIV. PrEP, when taken as indicated, is highly effective, and yet many who might benefit do not receive a prescription.

http://apretude.com/

According to preliminary data released by the CDC[2], in 2022, only about 36% of the 1.2 million people who could benefit from PrEP were prescribed it.

The CDC[3] also estimates that only 10% for women who could benefit from PrEP receive a prescription for it.

October 21 marks the start of PrEP Aware Week which shines a light on the importance of HIV prevention and the communities that are disproportionately impacted by HIV. The dedicated week is a time to educate everyone on the incidence rates of HIV, who could benefit from PrEP, and where to learn more about the different options available, including a daily pill or a long-acting injectable.
On Wednesday, October 23, Dr. Kimberly Smith, Head of Research and Development at ViiV Healthcare, will discuss ViiV’s comprehensive and innovative approach to HIV prevention and treatment and the role of prevention in ending the HIV epidemic once and for all.

Interview courtesy: ViiV Healthcare

The post THE ROLE OF PREVENTION IN ENDING THE HIV EPIDEMIC FOR ALL appeared first on Good News!.